FAMOTIDINE
- Product NDC
- 72603-564
- Requested package NDC
- 72603-564-01
- 11-digit product format
- 726030564
- Labeler code
- 72603
- Product ID
- 72603-564_4af90b5d-f47a-4436-8e24-4cb7e5b758b3
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- FAMOTIDINE
- Dosage form
- POWDER, FOR SUSPENSION
- Route
- ORAL
- Labeler
- NorthStar Rx LLC
- Application
- ANDA219091
- Marketing category
- ANDA
- Marketing start
- 2026-10-01
- Substance
- FAMOTIDINE
- Active strength
- 40 mg/5mL
- Pharmacologic classes
- Histamine H2 Receptor Antagonists [MoA], Histamine-2 Receptor Antagonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A219091-001 | FAMOTIDINE | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A219091-001 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | 6a471c1ec25d… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219091-001 | FAMOTIDINE | 40MG/5ML | FOR SUSPENSION / ORAL | AB | 2025-07-09 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A219091-001 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A219091-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A219091-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A219091-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A219091-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219091-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A219091-001 | AB | 1 | 6a471c1ec25d… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219091-001 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- FAMOTIDINE
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| FAMOTIDINE | 40 mg/5mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 5QZO15J2Z8 | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 310274 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 4af90b5d-f47a-4436-8e24-4cb7e5b758b3 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| FAMOTIDINE | FAMOTIDINE | NorthStar Rx LLC | 4af90b5d-f47a-4436-8e24-4cb7e5b758b3 | 2026-08-04 | Warnings, Adverse reactions | 219091 ANDA219091 72603-564-01 72603-564 72603056401 |
| FAMOTIDINE | FAMOTIDINE | Aurobindo Pharma Limited | 18066b80-1ec6-4092-80d9-70adb0ecac85 | 2026-01-09 | Warnings, Adverse reactions | 219091 ANDA219091 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 72603-564-01 | 72603056401 | 50 mL in 1 BOTTLE (72603-564-01) | 50 ml | 2026-10-01 | No | No | Current |